Sage Therapeutics said Thursday its drug to treat moderate and severe postpartum depression met the main goal in two late-stage studies.

The stock soared as much as 50 percent in premarket on Thursday.

The drug, brexanolone, achieved lower rates of depression in patients compared with a placebo in both trials.

Postpartum depression is a common complication of childbirth that affects about 10 to 20 percent of women giving birth in the United States, the company said.

—CNBC’s Berkeley Lovelace Jr. contributed to this report.

Source: Investment Cnbc
Sage Therapeutics shares soar after postpartum depression drug meets main goal